[Featured Stock] SK Chemicals Rises 7% on AstraZeneca's Anticipated US FDA Approval
[Asia Economy Reporter Minji Lee] SK Chemicals is showing a surge of over 7% during trading hours. This appears to reflect expectations that the AstraZeneca vaccine, which it manufactures under contract, will receive emergency use authorization from the U.S. Food and Drug Administration (FDA).
At 10:52 a.m. on the 18th, SK Chemicals was trading at 374,000 KRW, up 7.01% from the previous trading day. During the day, SK Chemicals traded as high as 378,000 KRW.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Jeong Yu-kyung Is a Neighbor"...Itaewon Standalone House with Record 23.2 Billion Won Appraisal Up for Auction [Real Estate AtoZ]
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
On the 17th (local time), Dr. Fauci, director of the National Institute of Allergy and Infectious Diseases, said regarding the approval of AstraZeneca’s vaccine, “Data will be sent to the FDA within one week or at most two weeks.” He added, “A committee must be convened to review whether the package for emergency use authorization is appropriate and to monitor safety, but (this process) will definitely take weeks, not months.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
